Pharmacokinetics of ofloxacin in patients on haemodialysis treatment.
Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After several doses of ofloxacin, saturation of the tissues and a rediffusion of ofloxacin from the tissues during haemodialysis has to be assumed. This equalizes the rate of elimination, and the serum ofloxacin concentration did not change during the last 2 hours of haemodialysis. The negative influence of phosphate binders on the resorption of ofloxacin can be confirmed. The following ofloxacin dosage regimen is recommended in haemodialysis patients: 200 mg initially, 100 mg loading dose after the first haemodialysis, then 100 mg daily.
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000097:blood / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D013997:Time Factors
D000890:Anti-Infective Agents; D010078:Oxazines; D015242:Ofloxacin